IREN Form 144 Filed for 1,000,000 Ordinary Shares via B. Riley
Rhea-AI Filing Summary
IREN Limited filed a Form 144 notifying the proposed sale of 1,000,000 ordinary shares through B. Riley Securities on NASDAQ with an approximate aggregate market value of $33,131,000. The filing lists total shares outstanding as 274,282,163 and an approximate sale date of 09/11/2025. Acquisition history for the shares to be sold is provided: 490,732 shares originally received from the issuer on 11/06/2018 and three restricted-stock-unit-related lots totaling 509,268 shares with acquisition dates in 06/19/2023 and 07/01/2023 (vested July 1, 2024) paid as remuneration. The filing also discloses recent related transactions: two option-related sales of 500,000 shares each on 09/03/2025 and 09/04/2025 with gross proceeds shown.
Positive
- Form 144 clearly identifies the broker (B. Riley Securities) and the exchange (NASDAQ) for the proposed sale
- Filing provides specific acquisition dates and payment types for the lots to be sold, aiding Rule 144 compliance review
- Disclosure includes recent related transactions with gross proceeds figures for option-related sales on 09/03/2025 and 09/04/2025
Negative
- None.
Insights
TL;DR
The Form 144 records a planned block sale of 1,000,000 IREN ordinary shares via B. Riley with an indicated market value of $33.13 million, and documents recent option-related disposals.
Detail: The filing supplies specific share counts, acquisition dates, and payment natures, allowing verification of Rule 144 eligibility windows for the lots disclosed. The reported outstanding share count provides context to the size of the proposed sale. Recent option exercises and reported gross proceeds on early-September sales are documented and relevant to near-term share supply.
TL;DR
The notice is a routine insider sale disclosure that includes vesting and issuer-issued shares and confirms the signer asserts no undisclosed material adverse information.
Detail: The form includes a standard representation regarding material adverse information and references potential Rule 10b5-1 plans without providing plan adoption dates. The filing properly identifies the broker and supplies acquisition provenance for each lot, supporting compliance with disclosure requirements.